We claim:

1. A solid dressing comprising an effective amount of fibronectin.

2. The solid dressing according to claim 1, which contains at least 0.5 to 1.0% of fibronectin by weight.

3. The solid dressing according to claim 2, wherein the fibronectin comprises plasma fibronectin, recombinant fibronectin, biologically active fragments of plasma fibronectin and biologically active fragments of recombinant fibronectin.

4. The solid dressing according to claim 3, wherein the fibronectin has substantially the same biological activity before and after the fibronectin is incorporated into the dressing.

5. The solid dressing according to claim 3, wherein the fibronectin is human fibronectin.

6. The solid dressing according to claim 3, wherein the fibronectin is fibronectin from a non-human animal.

7. The solid dressing according to claim 3, further comprising an effective amount of a wound healing promoter other than fibronectin.

8. The solid dressing according to claim 7, wherein the wound healing promoter other than fibronectin is selected from the group

consisting of thrombospondin, laminin, vitronectin, fibrinogen, or growth factors.

9. A pharmaceutical delivery system comprising a fibrous dressing containing an effective amount of fibronectin.

10. The pharmaceutical delivery system according to claim 9, wherein the fibrous dressing comprises a plant polysaccharide.

11. The pharmaceutical delivery system according to claim 10, wherein the plant polysaccharide is selected from the group consisting of alginates, carrageenans, and cellulose derivatives.

12. The pharmaceutical delivery system according to claim 9, wherein the fibrous dressing containing an effective amount of fibronectin is solid before contact with an exudating wound and is at least partially a gel after contact with an exudating wound.

13. The pharmaceutical delivery system according to claim 11, comprising a fibronectin-plant polysaccharide dressing wherein the concentration of fibronectin in the fibronectin-plant polysaccharide dressing is about 80μg/mm^2.

14. The pharmaceutical delivery system according to claim 11, comprising a fibronectin-polysaccharide dressing wherein at least 80% of the fibronectin is absorbed in a dermal layer of a deepithelialized skin diffusion cell system after 12 hours.

15. The pharmaceutical delivery system according to claim 9, wherein the fibrous dressing comprises a tissue matrix system.

16. The pharmaceutical delivery system according to claim 9, wherein the fibronectin is human fibronectin.

17. The pharmaceutical delivery system according to claim 9, wherein the fibronectin is fibronectin from a non-human animal.

18. The pharmaceutical delivery system according to claim 9, further comprising an effective amount of a wound healing promoter other than fibronectin.

19. The pharmaceutical delivery system according to claim 18, wherein the wound healing promoter other than fibronectin is selected from the group consisting of thrombospondin, laminin, vitronectin, fibrinogen or growth factors.

20. A method of producing a solid wound dressing according to claim 1 comprising the steps of

a) mixing a dispersion of insoluble fibers and a solution of fibronectin to produce a homogeneous mixture; and

b) freeze-drying the homogeneous mixture of step a to produce a solid wound dressing.

21. The method according to claim 20, wherein the dispersion of insoluble fibers contain some soluble fibers.

22. The method according to claim 20, wherein the insoluble fibers are soluble under some conditions.

23. The method according to claim 20, wherein the solution of fibronectin has a concentration of 10 mg/mL.

24. The method according to claim 20, wherein steps a) and b) are conducted under sterile conditions and comprising the further step of

c) placing and sealing the solid wound dressing of step b) in a sterile container under sterile conditions.